The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Transgenic Expression of Dominant-Active IDOL in Liver Causes Diet-Induced Hypercholesterolemia and Atherosclerosis in Mice
Abstract
Rationale : The E3 ubiquitin ligase inducible degrader of the low-density lipoprotein receptor (IDOL) triggers lysosomal degradation of the low-density lipoprotein receptor. The tissue-specific effects of the IDOL pathway on plasma cholesterol and atherosclerosis have not been examined. Objective : Given that the liver is the primary determinant of plasma cholesterol levels, we sought to examine the consequence of effect of chronic liver-specific expression of a dominant-active form of IDOL in mice. Methods and Results : We expressed a degradation-resistant, dominant-active form of IDOL (super IDOL [sIDOL]) in C57Bl/6J mice from the liver-specific albumin promoter (L-sIDOL transgenics). L-sIDOL mice were fed a Western diet for 20 or 30 weeks and then analyzed for plasma lipid levels and atherosclerotic lesion formation. L-sIDOL mice showed dramatic reductions in hepatic low-density lipoprotein receptor protein and increased plasma low-density lipoprotein cholesterol levels on both chow and Western diets. Moreover, L-sIDOL mice developed marked atherosclerotic lesions when fed a Western diet. Lesion formation in L-sIDOL mice was more robust than in apolipoprotein E*3 Leiden mice and did not require the addition of cholate to the diet. Western diet–fed L-sIDOL mice had elevated expression of liver X receptor target genes and proinflammatory genes in their aortas. Conclusions : Liver-specific expression of dominant-active IDOL is associated with hypercholesterolemia and a marked elevation in atherosclerotic lesions. Our results show that increased activity of the IDOL pathway in the liver can override other low-density lipoprotein receptor regulatory pathways leading to cardiovascular disease. L-sIDOL mice are a robust, dominantly inherited, diet-inducible model for the study of atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Transient or transgenic hepatic expression of Idol dramatically decreases the level of LDLR in the liver and results in a plasma lipid profile that phenocopies that of LDLR-KO mice.
“Transient or transgenic hepatic expression of Idol dramatically decreases the level of LDLR in the liver and results in a plasma lipid profile that phenocopies that of LDLR-KO mice [62,71,72].”
From The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms (2025) · cites this paper as [72]
The Results (Generation of L-sIDOL transgenic mice; page unavailable) report markedly reduced hepatic LDLR after transgenic expression. The plasma-lipid Results report increased LDL cholesterol and some similarities to LDLR-KO mice, but cholesterol and triglyceride elevations did not reach KO levels. This paper studies chronic transgenic expression, not transient hepatic expression. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chasman, D. I., Paré, G., Mora, S., Hopewell, J. C., Peloso, G., Clarke, R., Cupples, L. A., Hamsten, A., Kathiresan, S., Mälarstig, A., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000730 · Cited by 337
Weissglas-Volkov, D., Calkin, A. C., Tusie-Luna, T., Sinsheimer, J. S., Zelcer, N., Riba, L., Tino, A. M. V., Ordoñez-Sánchez, M. L., Cruz-Bautista, I., Aguilar-Salinas, C. A., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45504 · Cited by 66
Self-citation
Flagged first, then by citations
Research works printed but not linked: 14
- 10.1126/science.1168974 · DOI · Paper page
- 10.1073/pnas.1111589108 · DOI · Paper page
- 10.1128/MCB.01469-10 · DOI · Paper page
- 10.1093/eurheartj/ehs472 · DOI
- 10.1126/science.3513311 · DOI · Paper page
- 10.1172/JCI118532 · DOI
- 10.1016/0021-9150(85)90138-8 · DOI
- 10.1161/atvbaha.112.300263 · DOI
- 10.1172/JCI117179 · DOI
- 10.1172/JCI117915 · DOI
- 10.1126/science.1411543 · DOI · Paper page
- 10.1161/01.atv.0000243925.65265.3c · DOI
- 10.1161/atvbaha.107.142570 · DOI
- 10.1016/j.atherosclerosis.2009.11.043 · DOI
Cited by
Sorted by citations
Choi, J., Gao, J., Kim, J., Hong, C., Kim, J., & Tontonoz, P. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad1904 · Cited by 49
Self-citationIDOL regulates systemic energy balance through control of neuronal VLDLR expression
Lee, S. D., Priest, C., Bjursell, M., Gao, J., Arneson, D. V., Ahn, I. S., Diamante, G., van Veen, J. E., Massa, M. G., Calkin, A. C., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0127-7 · Cited by 26
Self-citationAdi, D., Lu, X.-Y., Fu, Z.-Y., Wei, J., Baituola, G., Meng, Y.-J., Zhou, Y.-X., Hu, A., Wang, J.-K., Lu, X.-F., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312589 · Cited by 24
The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms
Ndoj, K., Meurs, A., Papaioannou, D., Bjune, K., & Zelcer, N. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119082 · Cited by 17
Metadata
- Authors
- Calkin, A. C., Lee, S. D., Kim, J., Van Stijn, C. M. W., Wu, X.-H., Lusis, A. J., Hong, C., Tangirala, R. I., & Tontonoz, P.
- Affiliations
- From the Departments of Pathology and Laboratory Medicine (A.C.C., S.D.L., X.-H.W., C.H., P.T.), Department of Medicine, Division of Endocrinology (J.K., C.M.W.V.S., R.I.T.), Department of Medicine, Division of Cardiology (X.-H.W., A.J.L.), and Departments of Human Genetics and Microbiology Immunology and Molecular Genetics (A.J.L.), David Geffen School of Medicine, University of California, Los Angeles; Howard Hughes Medical Institute, Los Angeles, CA (A.C.C., S.D.L., C.H., P.T.); and Baker IDI...
- Venue
- Circulation Research
- Published
- 2014-08
- Volume
- 115
- Issue
- 4
- Pages
- 442-449
- ISSN
- 0009-7330
- 1524-4571
- PMC
- PMC4119488
- Cited by
- 27
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review